132 related articles for article (PubMed ID: 18022514)
1. Use of recombinant activated factor VII in a Jehovah's Witness patient.
Hsieh A; Cheong I
Am J Emerg Med; 2007 Nov; 25(9):1085.e1-2. PubMed ID: 18022514
[No Abstract] [Full Text] [Related]
2. Severe gastrointestinal haemorrhage responding to recombinant factor VIIa in a Jehovah's Witness with refractory immune thrombocytopenia.
Virchis A; Hughes C; Berney S
Hematol J; 2004; 5(3):281-2. PubMed ID: 15167918
[No Abstract] [Full Text] [Related]
3. Successful treatment of intestinal hemorrhage in a Jehovah's Witness patient.
Veneri D; Franchini M
Am J Hematol; 2005 Aug; 79(4):344-5. PubMed ID: 16044447
[No Abstract] [Full Text] [Related]
4. Splenic embolization in a Jehovah's Witness: role of recombinant human factor VIIa.
Mindikoglu AL; Anantharaju A; George M; Leone N; Bejna J; Van Thiel DH
Hepatogastroenterology; 2003; 50(53):1697-9. PubMed ID: 14571820
[TBL] [Abstract][Full Text] [Related]
5. Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa.
Sniecinski RM; Chen EP; Levy JH; Szlam F; Tanaka KA
Anesth Analg; 2007 Apr; 104(4):763-5. PubMed ID: 17377078
[TBL] [Abstract][Full Text] [Related]
6. Recombinant factor VIIa for major obstetric haemorrhage in a Jehovah's Witness.
Laird R; Carabine U
Int J Obstet Anesth; 2008 Apr; 17(2):193-4. PubMed ID: 18308545
[No Abstract] [Full Text] [Related]
7. The use of recombinant factor viia in a jehovah's witness with auto-immune thrombocytopenia and post-splenectomy haemorrhage.
Waddington DP; McAuley FT; Hanley JP; Summerfield GP
Br J Haematol; 2002 Oct; 119(1):286-8. PubMed ID: 12358947
[No Abstract] [Full Text] [Related]
8. Recombinant human coagulation factor VIIa in Jehovah's Witness patients undergoing liver transplantation.
Jabbour N; Gagandeep S; Peilin AC; Boland B; Mateo R; Genyk Y; Selby R; Zeger G
Am Surg; 2005 Feb; 71(2):175-9. PubMed ID: 16022020
[TBL] [Abstract][Full Text] [Related]
9. A Jehovah's Witness with complex abdominal trauma and coagulopathy: use of factor VII and a review of the literature.
Haan J; Scalea T
Am Surg; 2005 May; 71(5):414-5. PubMed ID: 15986972
[TBL] [Abstract][Full Text] [Related]
10. Recombinant activated factor VII for a warfarinised Jehovah's Witness with an acute subdural haematoma.
Goldberg R; Drummond KJ
J Clin Neurosci; 2008 Oct; 15(10):1164-6. PubMed ID: 17702584
[TBL] [Abstract][Full Text] [Related]
11. The contemporary approach to the care of Jehovah's witnesses.
Hughes DB; Ullery BW; Barie PS
J Trauma; 2008 Jul; 65(1):237-47. PubMed ID: 18580506
[TBL] [Abstract][Full Text] [Related]
12. Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven).
Tanaka KA; Waly AA; Cooper WA; Levy JH
Anesthesiology; 2003 Jun; 98(6):1513-5. PubMed ID: 12766668
[No Abstract] [Full Text] [Related]
13. Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding.
Kandane-Rathnayake RK; Isbister JP; Zatta AJ; Aoki NJ; Cameron P; Phillips LE;
ANZ J Surg; 2013 Mar; 83(3):155-60. PubMed ID: 23035873
[TBL] [Abstract][Full Text] [Related]
14. Administration of four-factor prothrombin complex concentrate for a life-threatening bleed in a Jehovah's Witness patient.
Cole JL; McLeod ND
Blood Coagul Fibrinolysis; 2018 Jan; 29(1):120-122. PubMed ID: 28938310
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human erythropoietin therapy in critically ill Jehovah's Witnesses.
Ball AM; Winstead PS
Pharmacotherapy; 2008 Nov; 28(11):1383-90. PubMed ID: 18956998
[TBL] [Abstract][Full Text] [Related]
16. Use of recombinant activated factor VII for reduction of perioperative blood loss during elective surgical correction of spine deformity in a Jehovah's Witness. Case report.
Kącka K; Kącki W; Merak J; Błęka A
Ortop Traumatol Rehabil; 2010; 12(5):448-58. PubMed ID: 21057153
[TBL] [Abstract][Full Text] [Related]
17. Use of recombinant activated factor VII in a patient with severe thrombocytopenia due to myelodysplastic syndrome with uncontrolled gastrointestinal bleeding.
Ozcelik T; Ozkocaman V; Ozkalemkas F; Ali R; Altundal Y; Ozkan A; Tunali A
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):385-6. PubMed ID: 17473584
[No Abstract] [Full Text] [Related]
18. Mortality risk stratification in severely anaemic Jehovah's Witness patients.
Beliaev AM; Marshall RJ; Smith W; Windsor JA
Intern Med J; 2012 Mar; 42(3):e1-3. PubMed ID: 22432994
[TBL] [Abstract][Full Text] [Related]
19. [Cardiac surgery in Jehovah's Witnesses. Experience in Santander, Spain].
Bernal JM; Naranjo S; Trugeda M; Sarralde A; Diago C; Revuelta JM
Rev Esp Cardiol; 2006 May; 59(5):507-9. PubMed ID: 16750149
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic use of factor IX concentrate in a Jehovah's Witness patient.
Bolliger D; Sreeram G; Duncan A; Molinaro RJ; Szlam F; Chen EP; Tanaka KA
Ann Thorac Surg; 2009 Nov; 88(5):1666-8. PubMed ID: 19853132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
